Related Experiment Video

Updated: Jun 6, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Exploration of synthetic lethal interactions as cancer drug targets

Hendrik J Kuiken1, Roderick L Beijersbergen

  • 1Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Future Oncology (London, England)
|December 15, 2010
PubMed

Insights

Identifying cancer-specific vulnerabilities through synthetic lethality is crucial for new drug development. RNA interference (RNAi) screens offer a powerful method to discover these targets, advancing cancer therapy.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • The search for cancer-specific drug targets is ongoing, focusing on vulnerabilities unique to tumor cells.
  • Synthetic lethal interactions, where combined genetic defects are lethal only in cancer cells, offer promising therapeutic avenues.
  • Targeting mutated proteins (e.g., RAS) or lost tumor suppressors (e.g., p53, APC, RB) presents challenges for conventional drug development.

Purpose of the Study:

  • To review the biological basis of synthetic lethal interactions in cancer.
  • To discuss lessons learned from existing targeted cancer therapeutics.
  • To explore the implementation of RNA interference (RNAi) for identifying novel synthetic lethal targets.

Main Methods:

  • Review of existing literature on synthetic lethality and targeted cancer therapies.
  • Discussion of the application of RNA interference (RNAi) in functional genomic screens.
  • Analysis of the potential of RNAi to identify cancer-specific vulnerabilities.

Main Results:

  • Synthetic lethal interactions represent a promising strategy for developing cancer-specific treatments.
  • Existing targeted therapies provide valuable insights into the complexities of cancer vulnerabilities.
  • RNAi-based functional genomic screens are enabling unbiased identification of novel synthetic lethal targets.

Conclusions:

  • Synthetic lethality offers a powerful paradigm for precision cancer medicine.
  • RNAi technology is instrumental in uncovering new therapeutic targets by screening for synthetic lethal interactions.
  • Advances in understanding synthetic lethality and utilizing RNAi promise to significantly improve cancer treatment outcomes.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...